A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

Breast Cancer Research

Volumn 15, Issue 2, 2013, Pages

  Brandão, Rita D ^a,b   Veeck, Jürgen ^a,b,c   Van de Vijver, Koen K ^a,b   Lindsey, Patrick ^a   de Vries, Bart ^a,b   van Elssen, Catharina H M J ^a,d   Blok, Marinus J ^a   Keymeulen, Kristien ^a,b   Ayoubi, Torik ^e   Smeets, Hubert J M ^a   Tjan Heijnen, Vivianne C ^a,b   Hupperets, Pierre S ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d Pharmacell   (Netherlands)

^e SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD34 ANTIGEN; CELECOXIB; KI 67 ANTIGEN; PLACEBO; MESSENGER RNA; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECTS; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84875821417     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3409     Document Type: Article

References (60)

1. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001, 84:473-483.
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899. 10.1016/j.cell.2010.01.025, 2866629, 20303878.
3. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193. 10.1038/nrc2809, 2898136, 20168319.
4. Friedman G, Ury H. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980, 65:723-733.
5. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996, 7:203-205. 10.1097/00001648-199603000-00017, 8834563.
6. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596. 10.1056/NEJM199112053252301, 1669840.
7. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316. 10.1056/NEJM199305063281805, 8385741.
8. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614. 10.1056/NEJM199509073331001, 7637720.
9. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146. 10.1097/00001648-199403000-00003, 8172988.
10. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin J-F, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000, 83:112-120. 2374529, 10883678.
11. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, APPROVe Trial Investigators A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682. 10.1053/j.gastro.2006.08.079, 17087947, APPROVe Trial Investigators.
12. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875. 10.1126/science.294.5548.1871, 11729303.
13. Bennett A, McDonald AM, Stamford IF, Charlier EM, Simpson JS, Zebro T. Prostaglandins and breast cancer. Lancet 1977, 310:624-626.
14. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu XB, Kobari Y, Pritchard K, Sessa WC, Hintze TH. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996, 78:58-64. 10.1161/01.RES.78.1.58, 8603506.
15. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
16. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866-12872.
17. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglendin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88:2692-2696. 10.1073/pnas.88.7.2692, 51304, 1849272.
18. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645. 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B, 11135226.
19. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 Is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569. 10.1074/jbc.M010787200, 11278747.
20. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, Lyon: IARC Press.
21. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours 2002, New York: Wiley-Liss, 6.
22. Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol 1993, 46:189-190. 501162, 8459046.
23. ArrayExpress. http://www.ebi.ac.uk/arrayexpress
24. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33:e175. 10.1093/nar/gni179, 1283542, 16284200.
25. Akaike H. Information theory and an extension of the maximum likelihood principle. Second International Symposium of Inference Theory 1973, 267-281. Budapest: Akadémiai Kiadó, Petrov B, Csàki F.
26. Ihaka R, Gentleman R. R: a language for data analysis and graphics. Journal of Computational and Graphical Statistics 1996, 5:299-314.
27. Lindsey J. Models for Repeated Measurements 1999, Oxford: Oxford University Press, 2.
28. Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane HC, Lempicki R. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:3.
29. van Iersel M, Kelder T, Pico A, Hanspers K, Coort S, Conklin B, Evelo C. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 2008, 9:399. 10.1186/1471-2105-9-399, 2569944, 18817533.
30. Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR, Evelo C. WikiPathways: pathway editing for the people. PLoS Biol 2008, 6:e184. 10.1371/journal.pbio.0060184, 2475545, 18651794.
31. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A'Hern R, Dowsett M. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002, 11:614-621.
32. Kaiser CL, Chapman BJ, Guidi JL, Terry CE, Mangiardi DA, Cotanche DA. Comparison of activated caspase detection methods in the gentamicin-treated chick cochlea. Hear Res 2008, 240:1-11. 10.1016/j.heares.2008.03.003, 2430666, 18487027.
33. da Silva BB, Pires CG, dos Santos AR, Castro-Leão A, Alencar AP, Lopes-Costa PV. Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer. Gynecol Obstet Invest 2009, 67:103-108. 10.1159/000165512, 18953168.
34. Chalkley H. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst 1943, 4:47-53.
35. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996, 393:101-104. 10.1016/0014-5793(96)00861-7, 8804434.
36. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007, 13:5243-5248. 10.1158/1078-0432.CCR-07-0182, 17875751.
37. Callegari AJ, Kelly TJ. Shedding light on the DNA damage checkpoint. Cell Cycle 2007, 6:660-666. 10.4161/cc.6.6.3984, 17387276.
38. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, Benamouzig R, Arber N. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006, 42:422-426. 10.1016/j.ejca.2005.11.009, 16426843.
39. Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003, 26:103-109.
40. Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 2008, 70:203-212. 10.1016/j.ijrobp.2007.08.065, 17996386.
41. Fatima N, Yi M, Ajaz S, Stephens RM, Stauffer S, Greenwald P, Munroe DJ, Ali IU. Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. Cancer Epidemiol Biomarkers Prev 2008, 17:3051-3061. 10.1158/1055-9965.EPI-08-0261, 18957522.
42. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, McLeod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 2008, 44:1754-1760. 10.1016/j.ejca.2008.05.010, 2566790, 18653328.
43. Orlichenko L, Radisky D. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 2008, 25:593-600. 10.1007/s10585-008-9143-9, 18286378.
44. Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer 2009, 8:81. 10.1186/1476-4598-8-81, 2765940, 19796390.
45. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol 2008, 30:42-51.
46. Lang S, Lauffer L, Clausen C, Lohr I, Schmitt B, Holzel D, Wollenberg B, Gires O, Kastenbauer E, Zeidler R. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 2003, 17:286-288.
47. Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, Lundholm K. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008, 8:5. 2935782, 18307280.
48. Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A, Salter J, Hills MJ, Lowe FM, A'Hern R, Nasiri N, Doody D, Iqbal J, Dowsett M. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002, 20:1026-1035. 10.1200/JCO.20.4.1026, 11844826.
49. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116. 10.1200/JCO.2005.04.005, 15998903.
50. Brueggemeier R, Quinn A, Parrett M, Joarder F, Harris R, Robertson F. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999, 140:27-35. 10.1016/S0304-3835(99)00050-6, 10403538.
51. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005, 23:2477-2492. 10.1200/JCO.2005.07.559, 15767642.
52. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001, 10:961-966.
53. Martin LA, Davies G, Weigel M, Betambeau N, Hills M, Salter J, Walsh G, A'Hern R, Dowsett M. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat 2010, 123:829-836. 10.1007/s10549-010-1100-z, 20697803.
54. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002, 277:18649-18657. 10.1074/jbc.M111415200, 11901151.
55. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 2004, 10:4062-4067. 10.1158/1078-0432.CCR-03-0463, 15217939.
56. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A, Lobelle JP. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008, 26:1253-1259. 10.1200/JCO.2007.13.3744, 18323548.
57. Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 2009, 20:615-620. 10.1093/annonc/mdn693, 19254941.
58. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012, 13:518-527. 10.1016/S1470-2045(12)70112-2, 22440112.
59. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612. 10.1016/S0140-6736(11)61720-0, 22440946.
60. Snead D, Bell J, Dixon A, Nicholson R, Elston C, Blamey R, Ellis I. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 1993, 23:233-238. 10.1111/j.1365-2559.1993.tb01195.x, 8225241.